Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach
- PMID: 29765792
- PMCID: PMC5951599
- DOI: 10.7759/cureus.2324
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer: A Promising Approach
Abstract
Locally advanced pancreatic cancer (LAPC) is characterized by poor prognosis and low response durability with standard-of-care chemotherapy or chemoradiotherapy treatment. Stereotactic body radiation therapy (SBRT), which has a shorter treatment course than conventionally fractionated radiotherapy and allows for better integration with systemic therapy, may confer a survival benefit but is limited by gastrointestinal toxicity. Stereotactic MRI-guided adaptive radiation therapy (SMART) has recently gained attention for its potential to increase treatment precision and thus minimize this toxicity through continuous real-time soft-tissue imaging during radiotherapy. The case presented here illustrates the promising outcome of a 69-year-old male patient with LAPC treated with SMART with daily adaptive planning and respiratory-gated technique.
Keywords: locally advanced pancreatic cancer; mri-guided adaptive radiotherapy; sbrt; smart.
Conflict of interest statement
The authors have declared financial relationships, which are detailed in the next section.
Figures
Similar articles
-
Stereotactic Magnetic Resonance-Guided Adaptive and Non-Adaptive Radiotherapy on Combination MR-Linear Accelerators: Current Practice and Future Directions.Cancers (Basel). 2023 Mar 30;15(7):2081. doi: 10.3390/cancers15072081. Cancers (Basel). 2023. PMID: 37046741 Free PMC article. Review.
-
Stereotactic MR-Guided Radiotherapy for Pancreatic Tumors: Dosimetric Benefit of Adaptation and First Clinical Results in a Prospective Registry Study.Front Oncol. 2022 Mar 9;12:842402. doi: 10.3389/fonc.2022.842402. eCollection 2022. Front Oncol. 2022. PMID: 35356227 Free PMC article.
-
Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.Cancer. 2017 Sep 15;123(18):3486-3493. doi: 10.1002/cncr.30706. Epub 2017 May 10. Cancer. 2017. PMID: 28493288 Free PMC article.
-
The role of biological dose-escalation for pancreatic cancer.Clin Transl Radiat Oncol. 2019 Apr 25;18:128-130. doi: 10.1016/j.ctro.2019.04.020. eCollection 2019 Sep. Clin Transl Radiat Oncol. 2019. PMID: 31341988 Free PMC article. Review.
-
Stereotactic MR-Guided Adaptive Radiotherapy for Pancreatic Tumors: Updated Results of the Montpellier Prospective Registry Study.Cancers (Basel). 2022 Dec 20;15(1):7. doi: 10.3390/cancers15010007. Cancers (Basel). 2022. PMID: 36612004 Free PMC article.
Cited by
-
Stereotactic body radiotherapy for pancreatic cancer - A systematic review of prospective data.Clin Transl Radiat Oncol. 2024 Jan 28;45:100738. doi: 10.1016/j.ctro.2024.100738. eCollection 2024 Mar. Clin Transl Radiat Oncol. 2024. PMID: 38370495 Free PMC article.
-
Online Adaptive MRI-Guided Stereotactic Body Radiotherapy for Pancreatic and Other Intra-Abdominal Cancers.Cancers (Basel). 2023 Nov 3;15(21):5272. doi: 10.3390/cancers15215272. Cancers (Basel). 2023. PMID: 37958447 Free PMC article.
-
Local Therapies for Hepatocellular Carcinoma and Role of MRI-Guided Adaptive Radiation Therapy.J Clin Med. 2023 May 17;12(10):3517. doi: 10.3390/jcm12103517. J Clin Med. 2023. PMID: 37240623 Free PMC article. Review.
-
MRI-Guided Radiation Therapy.Adv Oncol. 2021 May;1:29-39. doi: 10.1016/j.yao.2021.02.003. Epub 2021 May 19. Adv Oncol. 2021. PMID: 37064601 Free PMC article. No abstract available.
-
Dose Escalation for Pancreas SBRT: Potential and Limitations of using Daily Online Adaptive Radiation Therapy and an Iterative Isotoxicity Automated Planning Approach.Adv Radiat Oncol. 2023 Feb 2;8(4):101164. doi: 10.1016/j.adro.2022.101164. eCollection 2023 Jul-Aug. Adv Radiat Oncol. 2023. PMID: 36798731 Free PMC article.
References
-
- Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer controlled after 4 months of gemcitabine with or without erlotinib: the LAP07 randomized clinical trial. Hammel P, Huguet F, van Laethem JL, et al. JAMA. 2016;315:1844–1853. - PubMed
-
- Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer. Mahadevan A, Miksad R, Goldstein M, et al. Int J Radiat Oncol Biol Phys. 2011;81:0. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources